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Ob+ves. We sougbl lo evaluate the prognostic valoe of 
routine aoniovasive lesting-slress lballium-201 imaging, rest 
twwdimeasional et.bocardiograpby and rest equilibrium radionu- 
elide aag@npby-1 year after cati lrauspkmtalioo. 
lfaekpuad. Corouury artery vascutopatby is the most imv 
taut cause of late death after orhlopk cm&c lraosplaatalion. 
Several clInkal variables have beeu kleutified as risk factors for 
develupmeot of conumry vasculopalky. Traditional aooiovasive 
diagnostic testing has been sbmvn to be relatively insensitive hr 
ideolifyiug putieols wilb au@ograpbii wlby. 
II&&J&. Restdls of prwspsrtively acquired uooiavasive tesliq 
iu 47 conseeulive lra5splanl recipients aliie 1 year after lrans- 
pbwlalion were related lo subsequent suhvaf. Olber clhicaf 
v* previousfy shown to be associated wilb tke developmeat 
of corouary artery vasculopatby were also included in lbe analysis. 
Detection of cardiac allograft vawlopathy is a major concern 
in the follow-up ot patients who have undergone heart trans- 
plantation. Although infection and re,ection are the most 
common causes of death in the immediate postoperative 
period (1,2). coronary vaqulopathy is the most important 
cause of late death. Identification of subgroups of cardiac 
transplant recipients at high risk for the dalopment of 
clinically significant vasculopatby has been eI&e. Coronary 
angiography has been shown to be relatively insensitive for the 
detection of the characteristically diffuse dndings of cardiac 
allograft vasculopathy (3-7). In Contras!, most traditional 
therapeutic interventions for obstructive coronary atherorle- 
rosir are not effective in treating cardiac aliograft vasculopathy; 
the only treatment available for advanced disease is repeat 
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Rpsul%. The 5-year iunival rate after cat&c trdnsptaotation 
was 81%. By unka-hlc anal>& ,, +&rirurd@aphy @id-square 
9.211 aud stress lkallium-201 myacardiil perfiasioa imaging (cbi- 
square 16.76) were prrdiaie for survivat, wbemas rest equilii 
rium mdiiudii aq#gapby wav aoL Ctiaical rxmlriklors to 
sorvival were dooor age tcbi-square 456j, nsm!rer of tiuman 
leukocyte aaligen mismalcbes (cbi-quare 3.06) aad cokl iscbemic 
time (ebbsquare 3.23). By moltivariale analysis, stress nyocardii 
iknmyug7ema$ed lbe oufy s&i&au1 predii of suhval (risk 
: coaWeoce bllenal8.05 lo 0.89). 
co-. Normal lbaBii201 slmss myocwdhl f&ilsii 
buugiog I year after canlioc lraasplaalalioa is an iupmtal 
prediklor of +ar survival. 
(J Am cdl #niid 1996;28:183-9) 
cardiac transplantation (2). During the past decade numerous 
investigators have explored the value of traditional diagnostic 
methods to identify cardiac allograft vasculopathy. These 
studies suggested the relati>e insensitivity of noninvasive diag- 
nostic imaging for the detection of angiographic manifesta- 
tions of cardiac al&raft vasculopathy (6,8-13). 
The purpose of the present stu$ was to investigate the 
prognostic value of routine noninvasrve testing. such as rest 
equilibrium tadionuclide angiography. rest echocardiograpby 
and stress myocardial pctiion imaging. for predicting sur- 
vival after cardiac transplantation. 
Methods 
Patieuts. Consecutive patients who suwived for at least i 
year after orthotopic cardiac transplantation are he subjects of 
this study. Since 1988 it has become standard procedure at 
Yale-New Haven Medical Center to perform multiple csnin- 
vasive testing proceduresrest equilibrium &iiuctide an- 
giography. rest two-dimensional e-r& and quan- 
titative thallium-201 stress myocardial perfusion imaging-in 
all cardiac transplant recipients at annual follow-up visits. A 
total of 47 transplant recipients survived at least 1 year after 
transplantation and had prospectively acquired noninvasive 
testing. There were 38 men (SlcC) and 9 women (19%). Mean 
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recipient age vjas 46 t 10,years (range 15 to 62) at the time of 
transplantation. Wlean donor age was 27 2 lo years (range 14 
to 47). All patients had standard triple-drug therapy with 
azathioprine, cyclosporine and prednisone. All but four pa- 
tients were weaned from steroids by the end of the first year. 
Thirty-six recipients received monoclonal antibody therapy 
(OKT3) in the early posttransplantation period or as rescue 
therapy for resistant rejection. Four patients received antilym- 
phocyte globulin. Beginning in 1991, intravenous ganciclovir 
therapy was given as a prophylaxis against cytomegalovirus 
infection in all patients, except when the donor and recipient 
were seronegative for cytomegalovirus. No rigorous attempts 
were made to treat lipid abnormalities during the first year 
after transplantation. 
Patient data base. Clinical, noninvasive and invasive diag 
nostic testing data were entered prospectively in the Yale-New 
Haven Heart Failure and Cardiopulmonary Transplant Center 
data base. Selected clinical variables were extracted from the 
data base and categorized as dichotomous data: gender: recip- 
ient age >45 year; donor age >35 year; clinical history of 
diabetes mellitus, low density lipoprotein/high density lipopro- 
tein ratio >3.5, low density lipoprotein >160 mg/dl, recipient- 
donor ABO blood type identity, cold ischemic time of donor 
heart >160 min, cytomegalovirus serologic status of recipient 
before transplantation, cytomegalovirus donor-recipient mis- 
match, presence of cytotoxic anttbodies; antilymphocytic ther- 
apy (OKT3 and antilymphocyte globulin), total number of 
tissue-type mismatches at human leukocyte antigen (HLA)-A, 
HLA-B and HLA-DR loci (>3 mismatches), recurrent rejec- 
tion episodes (>2 episodes) and time to first rejection episode. 
In addition, cardiac angiography and endomyocardial biopsy 
report data, as well as verbatim reports of all noninvasive 
diagnostic test results, were available in the Yale-New Haven 
Hospital Diagnostic Imaging Database. 
Noninvasive testing. Rest equilibrium radionuclide angio- 
cardiography was performed using the modified in vivo Iabel- 
ing method with 20 to 25 mCi of technetium99m pertechne- 
tate (14). ‘Ihe gamma camera was equipped with a parallel- 
hole, general all-purpose collimator. The energy window 
(20%) was symmetrically placed over 140 keV. Images were 
obtained in three views: left anterior oblique, anterior and left 
lateral. Data were acquired in electrocardiographic synchro- 
nized frame mode (16 frames per R-R cycle) on computer in a 
64 X 64 matrix (word mode) for a total of 5 million counts. 
Left ventricular ejection fraction was calculated using pre- 
viously validated, automated edge-detection software (15). A 
varying left ventricular region of interest and cycle-.lcpt,dent 
background region were used. The background corrard 
volume curve was filtered to four Fourier harmonics. Left 
ventricular ejection fraction was determined from the fitted 
curve in the usual manner. 
Equilibrium radionuclide angiocardiography was consid- 
ered abnormal when the left ventricular ejection fraction was 
lower than 50% or when regional wall motion abnormalities 
were reported Paradoxic septum motion and dilation of both 
the atria were considered normal observations in the ortho- 
topic transplanted hearts (17). 
Rest two-dimensional echocardiography was performed 
with the patient in the left lateral decubitus position using an 
Acuson 128 Xp or HP 1500 echocardiographic imaging system. 
Each patient was examined in two orthogonal views from 
paras:,inal and apical windows. Echocardiographic studies 
were evaluated fu the presence of regional wall motion 
abnormalities. Although left ventricular ejection fraction was 
routinely estimated from echocardiographic studies, these data 
were not included in the present analysis because in our 
urstitution equilibrium radionuclide angiocardiography is con- 
ridered to assess radionuclide-computed lett ventricular ejec- 
tion fraction more precisely than echocardiography (lb). 
Echocardiography was considered abnormal if regional wall 
motion abnormalities were visually present. Paradoxic septum 
motion and dilation of both the atria were considered normal 
observations in the orthotopic transplanted heart (17). 
Thallium-201 stress myocardial perfusion imaging was per- 
formed after symptom-limited treadmill exercise using a mod- 
ified Naughton protocol. End points for exercise were angina1 
symptoms, 22 mm ST-T segment depression 0.08 s after the J 
point, ventricular arrhythmia, fatigue, dyspnea or hypotensive 
blood pressure response. Before, during and after exercise, 
IZlead electrocardiograms were recorded. At peak exercise, 
2.5 mCi of thallium-201 was injected intravenously and the 
patient was encouraged to exercise for at least 1 min longer. 
Four patients who were unable ;o perform physical exercise 
had dipyridamole coronary vasodilation in conjunction with 
thallium-201 myocardial perfusion imaging. These patients 
received a total of 0.57 mg!kg of dipyridamole over 4 min. 
When feasible, patients performed low level exercise to de- 
crease subdiaphragmatic radiopharmaceutical uptake. Thallium- 
201 was injected 4 min after completion of dipyridamole 
infusion. 
Planar myocardial perfusion imaging was performed using a 
computerized gamma camera equipped with a low energy, 
all-purpose, parallel-hole collimator. Imaging was performed 
in three projections: supine left anterior oblique, supine ante- 
rior and right side decubitus left lateral. The energy window of 
the gamma camera was set over the thallium-201 68-keV x-ray 
peak (25% windowj. All images were acquired for at least 
8 min, accumulating at least 600,000 counts in the field of view. 
Delayed imaging was performed 2% to 3 h later in the same 
projections and for the same time. Quantification of the 
thallium-201 images was performed as described and validated 
previously (18-20). 
Stress thallium-201 myocardial perfusion imaging was con- 
sidered abnormal if myocardial perfusion abnormalities (either 
reversible or lixed) were present on stress images by quantita- 
tive circumferential count distribution profile analysis. 
Biopsy and coronary angiograpby. Endomyocardial biopsy 
and cardiac catheterization were performed according to start: 
dard techniques. Ty@ally, a total of sii endomyocardial biopsy 
specimens were obtained. Rejection grades were defined ac- 
cording to the International Society for Heart and Lung 
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Transplantation: grade 1 = mild rejection; grade 2 = moderate 
focal rejection; grade 3 = moderate rejection. After the biopsy, 
right and left heart catheterization was performed in multiple 
views. Coronary angiograms were interpreted visually by expe- 
rienced angiographers immediately after cardiac catheteriza- 
tion. Quantitative coronary angiography was not performed 
routinely. Reported findings of “distal tapering” in the coro- 
nary arteries were not considered to be reliable because results 
of noninvasive stress testing were usually known at the time of 
coronary angiography. Only distinct focal abnormalities were 
entered in the data base. For purposes of this study, coronary 
angiography was o+Aered abnoi& if one or more discrete 
or tubular stenoses were reported. 
Table 1. Clinical Character&in of 47 Transplant Recipients 
46.1 i 9.5 
15-62 
18 (81%~ 
Recipient 
Age W 
Rallge 
Male gender 
Race 
white 
Black 
Hispanic 
Diabetes 
Lipid levels 
LDLHDL 
LDL (mpdl) 
CMV positive (pretranspant) 
CMV mismatch (donor positive. recipient negative) 
Donor 
hge w 
Range 
Cold khemic time (min) 
Range 
Clinical 
Antil~mphcqic therapy 
Time to first rejection (wk) 
Range 
Treated rejection episodes 
Range 
HLA mismatches 
Range 
ABD identity 
41(8&l%) 
2 (8%) 
2 (4%) 
12 (26%) 
Folhwp. The reports of yearly posttransplant noninva- 
sive and invasive examinations were retrieved from the data 
base and categorized by year of follow-up by one of the authors 
(P.V.), without knowledge of the patients’ subsequent clinical 
status. Original clinical reports representing the impressions of 
the interpreting physicians at the time of noninvasive testing, 
unaware of the future clinical outcome of the transplant 
recipient, were used. Although other noninvasive diagnostic 
imaging modalities may have been performed in the interval 
between the yearly follow-up visits, these data were not 
considered in the present analysis. The analysis is focused on 
the test results 1 year after transplantation. Autopsy reports of 
patients who died after the first year following transplantation 
were reviewed as well. 
3.03 -z 1.2! 
130 f 38 
13 (2%) 
9(19%) 
26.8 2 95 
14-47 
161 r46 
50-260 
40 (mi ) 
6.7 f. 5.6 
I-30 
I .2 I 0.9 
i-3 
4.6 + I .2 
O-6 
43 (91%) 
StatisthI analysis. Dichotomized noninvasive test results 
and clinical variables 1 year after cardiac transplantation were 
evaluated as potential predictors of long-term survival. In 
univariate analysis, the probability of survivmg was calculated 
using the Kaplan-Meier product-limited method. The log-rank 
test was used to test differences in survival curves. Because of 
the relatively small sample size, only those variables identified 
by univariate analysis as significant predictors of survival (p < 
0.05) were considered for inclusion in multivariate Cox regres- 
sion (proportional hazards) models. In the first Cox regression 
model the three noninvasive test results were entered to 
determine which ones were independently associated with 
survival, after adjustment for those clinical variables that were 
associated with survival (p < 0.10) at the univariate level. 
Data presented are mean value z SD, range or number (5) of patico:r. 
AEO = ABO blood typing: CMV = cytomrgalovbus: HDL = high density 
lipoprotein; HLA = human iehkgte antigen: LDL = low density lipoproteix 
Of 47 patients who survived for 1 year after transplantation, 
5 (11%) died afterward (range 13 to 47 months after trans- 
plantation). All five patients were men. of these deaths, four 
were due to acute myocardial infarction and one to infection 
(influenza A pneumonia). Three of the five patients who died 
had angiographic vasculopathy. Autopsy was perfotmed in 
three of the tive deceased patients. In each patient angio- 
graphic coronary vasculopathy was confirmed postmortem. 
Nonhwasive testing 1 year after hm~spiantation. One year 
after cardiac transplantation, 45 patients (%%) had all three 
noninvasive examinations, whereas 2 patients (4%) had two of 
the three noninvasive tests performed. Stress myocardial per- 
fusion imaging was performed in all 47 patients. Myocardial 
perfusion abnormalities were present in seven patients (15%). 
Three patients had 6xed defects, one patient had a reversible 
defect, two patients had partial reversible defects and one 
patient had a fixed defect with reverse redistribution. Qf seven 
patients with abnormal thaUium-201 imaging, four had focal 
vasculopathy by coronary angiography. Rest two-dimensional 
echocardiography was performed in 46 patients. Wall motion 
abnormalities were present in three patients (7%). Two pa- 
tients had dii global hypokinesis, and one patient had a 
regional wall motion abnormality. Qf ‘three patients with 
abnormal echocardiography, two had focal vasculopathy by 
coronary angiography. 
Results 
Patient characteristics and follow-up. Patient characteris- 
tics are shown in Table 1. No patients were lost to follow-up 
after 1 year. The mean survival time of those who survived 1 
year after cardiac transplantation was 45 c 20 months (range 
13 to 100). The survival rate 5 years after transplantation 
among patients who survived at least 1 year was 81% (Fig. 1). 
Thirty-four patients (72%) were treated for at least one 
rejection episode (mean 1.2 +- 0.9, range 1 to 3). After the first 
year, four recipients sustained (fatal) acute myocardial infarc- 
tions. Three patients had unexplained graft failure, successfully 
treated with steroids. Fiie patients had focal vasculopathy on 
angiography. 
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rro?!hs after transplantation 
Rest equilibrium radionuclide angiocardiography was per- 
formed in 46 patients. Twenty-eight patients had normal 
equilibrium radionuclide angiocardiography. Their mean left 
ventricular ejection fraction was 61 f 8% (range 50% to 83%). 
Eighteen patients (39%) had an abnormal equilibrium radio- 
nuciide an&cardiogram. Their mean left ventricular ejection 
fraction was 42 2 5% (range 26% to 50%). Twelve patients 
had an abnormal left ventricular ejection fraction and abnor- 
mal regional wall motion; five patients had an abnormal left 
ventricular ejection fraction and no regional wall motion 
abnormality; and one patient had a normal left ventricular 
ejection fraction but apical hypokinesis. Of 18 patients with 
abnormal rest equilibrium radionuclide angiocardiography, 4 
had focal vasculopathy by coronary angiography. 
Naninvasive testing, clinical variables and survival. Four 
of 7 patients with abnormal thallium-201 stress myocardial 
perfusion imaging and only 1 of 40 patients with normal stress 
myocardial imaging died during follow-up. (The four patients 
with abnormal thallium-201 stress imaging died of acute 
infarction, whereas the one patient with normal thallium-201 
imaging died of infection.) Two of 3 patients with abnormal 
echocardiography and 3 of 43 patients with normal echocardi- 
ography died during follow-up. Three of 18 patients with 
abnormal equilibrium radionuclide angiocardiography and 2 of 
28 patients with normal equilibrium radionuclide angiocardio- 
graphy died during follow-up. 
By univariate analysis, older donor age (~35 years; p = 
0.03), abnormal echocardiography at 1 year (p = 0.002) and 
abnormal stress thallium-201 imaging at 1 year (p < 0.0001) 
were significantly associated with poorer subsequent survival. 
Cold ischemic time (>160 min; p = 0.08) and the number of 
human leukocyte antigen mismatches (>3 mismatches; p = 
0.07) showed a borderline significant association with survival. 
Table 2 summarizes the results of univariate analysis, Proba- 
biIity of survival 5 years after transplantation was 97% for 
patients with normal thallium-201 stress myocardial perfusion 
imaging and 26% for patients with abnormal thallium-201 
JACC Vol. 28, No. 1 
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Figure 1. Probability of survival for 47 patients who 
survived orthotopic heart transplantation for at least 
12 months. Numbers in brackets indicate number of 
patients at risk. Survival 5 years after transplantation is 
818. 
stress myocardial perfusion imaging (Fig. 2). Probability of 
survival was 94% for patients with normal rest echocardiogra- 
phy and 33% for patients with abnormal rest echocardiogra- 
phy. There was no significant difference in predicted survival 
for patients with a normal versus an abnormal rest equilibrium 
radionuclide angiocardiogram at 1 year. 
In the first proportional hazards (Cox regression) model, 
the independent association between thallium-201 stress myo- 
cardial perfusion imaging and rest echocardiography with 
Table 2. Univariate Relation Between Clinical and Noninvasive 
Patient Variables and Survival (Kaplan-Meier Analysis) 
Variable Chi-Square p Value 
Recipient 
4% 
Gender 
Race 
Diabetes 
LDlfHDL 
LDL >I60 mgidl 
CMV posit& 
CMV mismatch 
Donor 
A% 
Cold ischrmic time 
Clinical 
Antilymphocytic therapy 
Time to first rejection episode 
No. of treated rejection episodes 
No. of HLA mismatches 
No. of ABO identity 
Noninvasive testing 
ERNA 
Echocardiography 
Stres thallium-201 imaging 
1.27 0.26 
1.11 0.29 
1.51 0.47 
0.008 0.93 
1.54 0.21 
0.08 0.78 
1.21 0.27 
1.77 0.18 
4.56 0.03 
3.23 0.07 
0.72 9.40 
0.35 0.55 
0.002 0.96 
3.06 0.08 
0.26 0.61 
1.22 0.27 
o.cm2 9.21 
16.76 0.fnlO1 
ABO = ABO blood typing; CMV = cytomegaloviros; ERNA = equilibrium 
radioouclide aogiocardiiphy; HDL = high de&y lipoprotein; HLA = 
human leukocyte antigen; LDL = low de&y lipoprotein. 
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Figure 2. Probability of survival in patients with nor- 
mal and abnormal stress thallium-201 (Tl-201) imaging 
at l-year follow-up (n = 47). Dashed line represents 
survival for patients with normal thallium-201 imaging 
(n = 40). Continoolis liw represents survival for 
patients with abnormal thallium-201 imaging (II = 7). 
Numbers in brackets indicate number of patients at 
risk. Patients with abnormal stress thallium-201 imag 
ing have a significantly (p < 0.0001) worse survival rate 
than patients with normal SIWES thallium-201 imaging. 
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survival was tested (rest equilibrium radionuclide angiocardio- 
graphy was not included in the model because it was not 
predictive of survival at the univariate level). As shown in 
Table 3, normal thallium-201 stress myocardial perfusion 
imaging 1 year after transplantation was the only significant 
independent predictor of survival (relative risk [RR] = 0.27; 
95% confidence interval [CI] 0.06 to 0.89). The results of the 
second proportional hazards model indicate that normal thal- 
lium-201 stress myocardial perfusion imaging 1 year after 
transplantation remained significantly associated with survival 
(RR = 0.19; 95% CI 0.03 to 0.60) when controlling for donor 
age, cold ischemic time and number of human leukocyte 
antigen mismatches (Table 4). 
Discussion 
This study focuses on the prognostic value of routine 
noninvasive testing 1 year after orthotopic cardiac transplan- 
tation. In multivariate analysis, normal stress myocardial per- 
fusion imaging at 1 year is the single most important predictor 
of long-term survival after heart transplantation. The proba- 
bility of survival 5 year after cardiac transplantation for 
patients with normal stress perfusion imaging at I year is 97%. 
The development of coronary artery vasculopathy after 
cardiac transplantation is recognized as an important limiting 
factor for long-term survival. Tbe angiographic incidence of 
vasculopathy has been reported to be 14% at 1 year, 37% at 3 
Table 3. Relation of Stress Thallium-201 Imaging and Rest 
Echocardiogrape to Survival After Transplantation (Cox 
proportional hazards), Adjusted for the Other Test - 
Riik 95% CFnfidenee P 
Variable Ratio Interval cbi-square V&l‘2 
Stres5tbaUium-2u1 0.3 0.06-0.1 4.61 0.03 
imaging 
Fsbmrdiihy 056 0.17-1.77 1.03 031 
years and SO% at 5 years (1,2,21.22). Because of the diffuse 
nature of the disease it is concehable that the presence and 
severity of coronary artery vasculopathy are underestimated by 
routine angiography (3.23). Recent studies with intracoronary 
ultrasound suggest that vasculopathic intimal thickening oc- 
curs frequently in cardiac transplant recipients (24). 
Several clinical variables, such as rejection (U), cytomega- 
lovirus infection (26), recipient gender, recipient age, donor 
age (27), history of diabetes mellitus (28), and fasting serum 
lipoproteins (29), have been identified to be associated with 
the development of vasculopathy and adverse outcome. Per- 
haps owing to the relatively small number of patients, these 
variables were not signihcantly related to survival in the 
present study. Only donor age was a significant predictor of 
survival by univariate analysis, but not by multivariate analysis. 
Cold ischemic time and the number of human leukocyte 
antigen mismatches only approached statistical significance in 
univariate analysis in the present study. 
Previous studies usually focused on the value of traditional 
noninvasive testing to identify cardiac allograft vasculopathy. 
These studies generally suggested a relative insensitivity of 
noninvasive diagnostic imaging to detect an&graphic mani- 
festations of cardiac ahograft vasculopathy (6,8-13). Smart et 
Tabte 4. Relation of Stress Thallium-201 Imaging to Survival After 
Transplantation (Cox propxtlonal hazards), Adjusted for Donor 
Age. Number of Human Leukocyte Antigen Mismatches and Cold 
Isehemic Tie -- 
Risk 95% cintkkwe 
Variable Ralio Interval fJ$-Q~c p Value 
Stress thallium-Bl 0.19 0.031-0.60 8.14 0.0043 
~4% 
Donor as I .02 0.87-IS7 um 083 
Cotd iscbemic time I.00 0.9w.o ct.17 0.68 
HIA olismatches 0.77 0.30-2.70 0.23 0.63 
HIA = bumui leukocyte aatigee 
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al. (8) reported that rest regional walr motion abnormalities 
and depressed left ventricular ejection fraction by two- 
dimensional echocardiography were more sensitive than 
kllium-201 stress myocardial perfusion imaging for the de- 
tection of coronary vasculopathy. 
In the present study the prognostic value of long-term 
survival as determined by noni&asive testing was evaluated. 
Rest left ventricular ejection fraction by equilibrium radionu- 
elide angiocardiography was not a significant predictor of 
long-tern? survival. This can be explained by the relatively 
narrow range of left ventricular ejection fraction values at the 
l-year follow-up examination. Most patients had a left ventric- 
ular ejection fraction >40%. The Jikrcnlial predictive valoc 
of leri ventricular ejection fraction for future cardiac events in 
patients with coronary artery disease is less in the normal range 
than in the abnormal range (30). It is conceivable that assess- 
ment of left ventricular function by stress equilibrium radio- 
nuclide angiocardiography or stress echocardiography (31) 
would have comparable predictive value for survival as shown 
in the present study by stress myocardial perfusion imaging. 
Stress myocardial perfusion imaging was a strong predictor 
of 5-year survival. Of five patients who died, four (80%) had 
abnormal stress thallium-201 myocardial perfusion imaging 1 
year after transplantation. In contrast, only 3 of 40 (8%) 
patients alive at 5 years had abnormal stress thallium-201 
imaging. Probability of survival 5 year after cardiac transplan- 
tation was 97% for patients with normal stress myocardial 
perfusion imaging and only 26% for patients with abnormal 
stress myocardial perfusion imaging at 1 year. These findings 
concur with those by Ciliberto et al. (32), who found a similar 
prognostic value for stress myocardial perfusion imaging. 
Study limitations. The number of patients included in the 
present analysis and the number of cardiac events during 
follow-up are relatively small. This does not allow for analysis 
of subgroups of patients (e.g., patients with reversible myocar- 
dial perfusion defects versus patients with tied defects). 
Furthermore, the relatively small number of patients does not 
allow for the inclusion of more variables in the multivariate 
analysis for loss of statistical power. Finally, the aim of this 
study was not to compare noninvasive and invasive assessment 
of coronary vasculopathy. We do not routinely perform quan- 
titative contrast angiography or intracoronary ultrasound for 
assessment of posttransplant va@opathy. These methods 
may have value in predicting outcome after cardiac transplan- 
tation. 
Condosions. Stress myocardial perfusion imaging I year 
after cardiac transp!antation is an important predictor gf 
s-year survival. This could have important implications for the 
cost-effective management of transplant recipients. However, a 
thorough cost atalysis is beyond the scope of the present study. 
Normal ih&tmQOl stress myoeardial perfusion imaging 
identilks a low risk group of cardiac transplant recipients. 
Patients with abnormal thallium-201 stress imaging are poten- 
tially at high risk and deserve close subsequent monitoring. 
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